Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)
To evaluate the safety and tolerability of escalating doses GX-I7 in combination with standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with refractory or relapsed TNBC
Triple Negative Breast Cancer
DRUG: GX-I7|DRUG: Pembrolizumab(KEYTRUDAÂ®)|DRUG: Cyclophosphamide
Incidence and nature of DLTs, To evaluate the safety and tolerability of GX-I7 in combination with standard dose pembrolizumab, during the first 5 weeks|Incidence, nature and severity of adverse events, graded according to NCI CTCAE v5.0, up to 24month|Objective response rate (ORR), defined as percentage of subjects with a complete response (CR) or partial response (PR) per RECIST v.1.1, up to 24month
To evaluate the safety and tolerability of escalating doses GX-I7 in combination with standard dose pembrolizumab, and to evaluate objective response rate (ORR) in subjects with refractory or relapsed TNBC